Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide

The use of high-efficacy disease-modifying therapies (DMTs) early in the course of multiple sclerosis (MS) has been shown to improve clinical outcomes and is becoming an increasingly popular treatment strategy. As a result, monoclonal antibodies, including natalizumab, alemtuzumab, ocrelizumab, ofat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gklinos, Panagiotis, Dobson, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223026/
https://www.ncbi.nlm.nih.gov/pubmed/37242553
http://dx.doi.org/10.3390/ph16050770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223026/
https://www.ncbi.nlm.nih.gov/pubmed/37242553
http://dx.doi.org/10.3390/ph16050770

Ejemplares similares